Creative Medical Technology Holdings, Inc. Common Stock (CELZ) is a publicly traded Healthcare sector company. As of November 13, 2026, CELZ trades at $0.54 with a market cap of $4.68M and a P/E ratio of 0.00. CELZ moved -14.35% today. Year to date, CELZ is -74.07%; over the trailing twelve months it is -81.24%. Its 52-week range spans $0.53 to $6.25. Analyst consensus is buy with an average price target of $20.00. Rallies surfaces CELZ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Creative Medical reports 65% reduction in average pain scores in Ultrasome knee osteoarthritis pilot study: Creative Medical Technology Holdings reported a 93% response rate in a 30-patient knee osteoarthritis pilot of its investigational Ultrasome therapy. Over six months, average pain scores fell approximately 65%, WOMAC scores declined 52%, and no serious adverse events were reported.
| Metric | Value |
|---|---|
| Price | $0.54 |
| Market Cap | $4.68M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.25 |
| 52-Week Low | $0.53 |
| Volume | 152.56K |
| Avg Volume | 0 |
| Revenue (TTM) | $6.00K |
| Net Income | $-6.00M |
| Gross Margin | 63.43% |
1 analysts cover CELZ: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $20.00.